Aglatimagene besadenovec is under clinical development by Candel Therapeutics and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Aglatimagene besadenovec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aglatimagene besadenovec overview
Aglatimagene besadenovec is under development for the treatment of non-small cell lung cancer, high grade glioma, glioblastoma multiforme, recurrent glioblastoma multiforme, anaplastic astrocytoma, recurrent, advanced non-metastatic pancreatic ductal adenocarcinoma and prostate cancer. The therapeutic candidate consists of (AdV-tk) adenoviral replication-defective engineered gene construct encoding the thymidine kinase gene derived from herpes simplex virus (HSV). It is administered through intra-tumoral route and is being developed based on enLIGHTEN Discovery Platform.
The therapeutic candidate was also under development for the treatment of malignant glioma and ependymomas.
Candel Therapeutics overview
Candel Therapeutics is a clinical stage biopharmaceutical company. It manufactures, develops and tests cancer immunotherapy drugs and gene-based biologics. The company lead products candidate includes CAN-2409 and CAN-3110 for the treatment of non-small cell lung cancer (NSCLC), advanced non-metastatic pancreatic adenocarcinoma, prostate cancer, pancreatic cancer and recurrent high-grade glioma (rHGG). Candel Therapeutics also utilizes its Candel’s enlighten a systematic, HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. Candel Therapeutics is headquartered in Needham, Massachusetts, the US.
For a complete picture of Aglatimagene besadenovec’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
